The stock of Aptevo Therapeutics Inc (APVO) has seen a -5.68% decrease in the past week, with a -55.15% drop in the past month, and a -67.76% decrease in the past quarter. The volatility ratio for the week is 12.80%, and the volatility levels for the past 30 days are at 14.27% for APVO. The simple moving average for the last 20 days is -42.68% for APVO’s stock, with a simple moving average of -94.45% for the last 200 days.
Is It Worth Investing in Aptevo Therapeutics Inc (NASDAQ: APVO) Right Now?
Company’s 36-month beta value is 5.17.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APVO is 9.42M, and currently, short sellers hold a 0.14% ratio of that floaft. The average trading volume of APVO on September 26, 2024 was 6.52M shares.
APVO) stock’s latest price update
Aptevo Therapeutics Inc (NASDAQ: APVO)’s stock price has gone decline by -7.16 in comparison to its previous close of 0.18, however, the company has experienced a -5.68% decrease in its stock price over the last five trading days. accesswire.com reported 2024-09-18 that SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 9,090,910 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 18,181,820 shares of its common stock (the “Common Warrants”) at a purchase price of $0.33 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Analysts’ Opinion of APVO
Piper Jaffray, on the other hand, stated in their research note that they expect to see APVO reach a price target of $6. The rating they have provided for APVO stocks is “Overweight” according to the report published on October 05th, 2017.
APVO Trading at -54.28% from the 50-Day Moving Average
After a stumble in the market that brought APVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.23% of loss for the given period.
Volatility was left at 14.27%, however, over the last 30 days, the volatility rate increased by 12.80%, as shares sank -49.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -69.47% lower at present.
During the last 5 trading sessions, APVO rose by +0.80%, which changed the moving average for the period of 200-days by -97.79% in comparison to the 20-day moving average, which settled at $0.2809. In addition, Aptevo Therapeutics Inc saw -97.92% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APVO
Current profitability levels for the company are sitting at:
- -28.77 for the present operating margin
- 0.52 for the gross margin
The net margin for Aptevo Therapeutics Inc stands at -27.67. The total capital return value is set at -2.73. Equity return is now at value -243.74, with -115.20 for asset returns.
Based on Aptevo Therapeutics Inc (APVO), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -4.84. The debt to equity ratio resting at 1.13. The interest coverage ratio of the stock is -2.71.
Currently, EBITDA for the company is -28.31 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of -1.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In a nutshell, Aptevo Therapeutics Inc (APVO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
